Dhruv Mehta1, Priti Poojary2, Aparna Saha2, Supreet Kaur3, Shanti Patel4, Lavneet Chawla5, Arun Kumar5, Priya Simoes6, Deepthi Busayavalasa7, Girish Nadkarni2, Madhusudhan Sanaka8. 1. Department of Gastroenterology and Hepatolobiliary Disease, Westchester Medical Center at New York Medical College, 40 Sunshine Cottage Road, Skyline 2N-D08, Valhalla, NY, 10595, USA. dsmehta18@gmail.com. 2. Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. 3. Department of Hematology and Oncology, St. Joseph's Regional Medical Center, Paterson, NJ, USA. 4. Department of Internal Medicine, Maimonides Medical Center, Brooklyn, NY, USA. 5. Department of Internal Medicine, Westchester Medical Center at New York Medical College, Valhalla, NY, USA. 6. Division of Gastroenterology, Hepatology and Nutrition, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 7. Department of Internal Medicine, Advocate Christ Medical Center Oak Lawn, Oak Lawn, IL, USA. 8. Division of Gastroenterology and Hepatobiliary Diseases, Cleveland Clinic, Cleveland, OH, USA.
Abstract
BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) can be challenging in patients with decompensated cirrhosis (DC) due to increased risk of adverse events related to liver dysfunction. Limited data exist regarding its national utilization in patients with DC. We aim to determine the trends in utilization and outcomes of ERCP among patients with DC in US hospitalizations. METHODS: We identified hospitalizations undergoing ERCP (diagnostic and therapeutic) between 2000 and 2013 from the National Inpatient Sample (NIS) database and used validated ICD9-CM codes to identify DC hospitalizations. We utilized Cochrane-Armitage test to identify changes in trends and multivariable survey regression modeling for adjusted odds ratios (aOR) for adverse outcomes and mortality predictors. RESULTS: There were 43782 cases of ERCPs performed in DC patients during the study period. Absolute number of ERCPs performed in this population from 2000 to 2013 showed an upward trend; however, the proportion of DC patients undergoing ERCP remained stable. We noted significant decrease in utilization of diagnostic ERCP and an increase of therapeutic ERCPs (P < 0.01). There was a significant decrease in the mean length of stay for DC patients undergoing ERCP from 8.2 days in 2000 to 7.2 days in 2013 (P < 0.01) with an increase in the mean cost of hospitalization from $17053 to $19825 (P < 0.001). Mortality rates showed a downward trend from 2000 to 2013 from 13.6 to 9.6% (P < 0.01). Increasing age, Hispanic race, diagnosis of hypertension and diabetes mellitus, and private insurance were related to adverse discharges(P < 0.01). Increasing age, presence of hepatic encephalopathy, and sepsis were associated with higher mortality (P < 0.01). CONCLUSIONS: There is an increasing trend in therapeutic ERCP utilization in DC hospitalizations nationally. There is an overall decrease in mortality in DC hospitalizations undergoing ERCP. This improvement in mortality suggests improvement in both procedural technique and peri-procedural care as well as overall decreasing mortality in cirrhosis.
BACKGROUND: Endoscopic retrograde cholangiopancreatography (ERCP) can be challenging in patients with decompensated cirrhosis (DC) due to increased risk of adverse events related to liver dysfunction. Limited data exist regarding its national utilization in patients with DC. We aim to determine the trends in utilization and outcomes of ERCP among patients with DC in US hospitalizations. METHODS: We identified hospitalizations undergoing ERCP (diagnostic and therapeutic) between 2000 and 2013 from the National Inpatient Sample (NIS) database and used validated ICD9-CM codes to identify DC hospitalizations. We utilized Cochrane-Armitage test to identify changes in trends and multivariable survey regression modeling for adjusted odds ratios (aOR) for adverse outcomes and mortality predictors. RESULTS: There were 43782 cases of ERCPs performed in DC patients during the study period. Absolute number of ERCPs performed in this population from 2000 to 2013 showed an upward trend; however, the proportion of DC patients undergoing ERCP remained stable. We noted significant decrease in utilization of diagnostic ERCP and an increase of therapeutic ERCPs (P < 0.01). There was a significant decrease in the mean length of stay for DC patients undergoing ERCP from 8.2 days in 2000 to 7.2 days in 2013 (P < 0.01) with an increase in the mean cost of hospitalization from $17053 to $19825 (P < 0.001). Mortality rates showed a downward trend from 2000 to 2013 from 13.6 to 9.6% (P < 0.01). Increasing age, Hispanic race, diagnosis of hypertension and diabetes mellitus, and private insurance were related to adverse discharges(P < 0.01). Increasing age, presence of hepatic encephalopathy, and sepsis were associated with higher mortality (P < 0.01). CONCLUSIONS: There is an increasing trend in therapeutic ERCP utilization in DC hospitalizations nationally. There is an overall decrease in mortality in DC hospitalizations undergoing ERCP. This improvement in mortality suggests improvement in both procedural technique and peri-procedural care as well as overall decreasing mortality in cirrhosis.
Authors: Sumant Inamdar; Tyler M Berzin; Joshua Berkowitz; Divyesh V Sejpal; Mandeep S Sawhney; Ram Chutanni; Douglas K Pleskow; Arvind J Trindade Journal: Liver Int Date: 2016-03-24 Impact factor: 5.828
Authors: Daniel Baram; Feroza Daroowalla; Ruel Garcia; Guangxiang Zhang; John J Chen; Erin Healy; Syed Ali Riaz; Paul Richman Journal: Clin Med Circ Respirat Pulm Med Date: 2008-04-18
Authors: D Conte; D Barisani; C Mandelli; P Bodini; M Borzio; S Pistoso; M Segala; G P Aimo; M Fraquelli; P A Bianchi Journal: Am J Gastroenterol Date: 1991-11 Impact factor: 10.864
Authors: K R Maurer; J E Everhart; T M Ezzati; R S Johannes; W C Knowler; D L Larson; R Sanders; T H Shawker; H P Roth Journal: Gastroenterology Date: 1989-02 Impact factor: 22.682
Authors: F Prat; R Tennenbaum; P Ponsot; C Altman; G Pelletier; J Fritsch; A D Choury; P Bernades; J P Etienne Journal: Gastrointest Endosc Date: 1996-02 Impact factor: 9.427
Authors: Fasiha Kanwal; Ian M Gralnek; Ron D Hays; Angelique Zeringue; Francisco Durazo; Steven B Han; Sammy Saab; Roger Bolus; Brennan M R Spiegel Journal: Clin Gastroenterol Hepatol Date: 2009-03-21 Impact factor: 11.382